Table 1 Characteristics of the eligible trials included in the meta-analysis
Trial | No. of pts |  | Regimens (per arm) | No. of pts (per arm) | Male | Median age (range)(y) | PS 0-2/KPS≥50 | M* |
|---|---|---|---|---|---|---|---|---|
Gong JF | 40 | palliative | Gem-X** | 25 | 56% | 63 (45-76) | UK | UK |
2007[8] | Â | Â | Gem | 15 | 66.7% | 63 (45-76) | Â | Â |
Reni M | 104 | first line | PEFG | 52 | 46.2% | 62 (37-69) | 100% | 71% |
2005[9] | Â | Â | Gem | 47 | 40.7% | 59 (25-69) | 100% | 56% |
Gem versus Gem plus fluoropyrimidine | ||||||||
Cunningham D | 533 | first line | Gem/Cap | 267 | 60% | 62 (37-82) | 100% | 70% |
2009[10] | Â | Â | Gem | 266 | 58% | 62 (26-83) | 100% | 71% |
Bernhard J | 319 | palliative | Gem/Cap | 160 | 54% | 62 (27-83) | 100% | 80% |
2008[11] | Â | Â | Gem | 159 | 53% | 62 (36-84) | 100% | 79% |
Scheithauer W | 83 | first line | Gem/Cap | 41 | 66% | 64 (40-75) | 100% | UK |
2003[12] | Â | Â | Gem | 42 | 55% | 66 (39-75) | 100% | Â |
Berlin JD | 327 | first line | Gem/5-FU | 160 | 51.8% | 65.8 (28-84) | 100% | 89.4% |
2002[13] | Â | Â | Gem | 162 | 53.7% | 64.3 (33-85) | 100% | 90.1% |
Di Costanzo F | 94 | first line | Gem/5-FU | 45 | 63% | 62 (44-75) | 100% | 67% |
2005[14] | Â | Â | Gem | 49 | 48% | 64 (34-75) | 100% | 73% |
Riess H[15] | 473 | first line | Gem/5-FU | 235 | UK | UK | 100% | UK |
2005 | Â | Â | Gem | 238 | Â | Â | 100% | Â |
Gem versus Gem plus platinum | ||||||||
Louvet C | 313 | first line | Gem/Oxa | 157 | 60% | 61 (35-77) | 100% | 68% |
2005[16] | Â | Â | Gem | 156 | 53% | 60 (22-75) | 100% | 70% |
Poplin E | 824 | first line | Gem/Oxa | 272 | 45.6% | 63 (29-96) | 99.6% | 89.3% |
2009[17] | Â | Â | Gem | 275 | 56.4% | 63 (31-88) | 100% | 90.2% |
| Â | Â | Â | Gem FDR | 277 | 57.8% | 62 (36-87) | 99.6% | 88.8% |
Yan ZC | 60 | first line | Gem/Oxa | 30 | 63.3% | 58 (23-75) | 31.7% | UK |
2007[18] | Â | Â | Gem | 30 | 63.3% | 58 (23-75) | 31.7% | UK |
Colucci G | 400 | first line | Gem/DDP | 201 | 62.2% | 63 (35-75) | 100% | 84.6% |
2010[19] | Â | Â | Gem | 199 | 56.8% | 63 (37-75) | 100% | 82.9% |
Colucci G | 107 | first line | Gem/DDP | 53 | 66% | 60 (33-71) | 100% | 62% |
2002[20] | Â | Â | Gem | 54 | 50% | 63 (43-75) | 100% | 54% |
Wang XY | 42 | first line | Gem/DDP | 22 | 68.2% | 65 (37-76) | 100% | 68.2% |
2002[21] | Â | Â | Gem | 20 | 70.0% | 57 (35-60) | 100% | 50% |
Heinemann V | 195 | first line | Gem/DDP | 98 | 65.3% | 64 (37-82) | 100% | 80% |
2006[22] | Â | Â | Gem | 97 | 61.9% | 66 (43-85) | 100% | 78.9% |
Palmer DH | 50 | neoadjuvant | Gem/DDP | 26 | 50% | 66 (47-78) | 100% | UK |
2007[23] | Â | Â | Gem | 24 | 54% | 66 (40-79) | 100% | Â |
Li CP | 46 | first line | Gem/DDP | 21 | UK | UK | UK | UK |
2004[24] | Â | Â | Gem | 25 | Â | Â | Â | Â |
Kulke MH | 259 | first line | Gem/DDP | 66 | 56% | 59 (36-84) | 100% | UK |
2009[25] | Â | Â | Gem FDR | 64 | 66% | 59 (31-81) | 100% | UK |
| Â | Â | Â | Gem/Doc | 65 | 62% | 63 (41-79) | 100% | UK |
| Â | Â | Â | Gem/CPT-11 | 64 | 68% | 61 (32-77) | 100% | UK |
Viret F | 83 | first line | Gem/DDP | 42 | UK | 62 | 100% | 81% |
2004[26] | Â | Â | Gem | 41 | UK | 63 | 100% | 78% |
Gem versus camptothecin | ||||||||
Stathopoulos GP | 130 | first line | Gem/CPT-11 | 60 | 65% | 64 (31-84) | 100% | 78% |
2006[27] | Â | Â | Gem | 70 | 60% | 64 (44-83) | 100% | 86% |
Rocha Lima CM | 360 | first line | Gem/CPT-11 | 180 | 57.2% | 63 (39-81) | 97.2% | 82.2% |
2004[28] | Â | Â | Gem | 180 | 53.3% | 60 (32-83) | 93.9% | 80.6% |
Abou-Alfa GK | 349 | first line | Gem/exatecan | 175 | 53% | 63 (36-85) | 99% | 79% |
2006[29] | Â | Â | Gem | 174 | 57% | 62 (30-84) | 100% | 78% |
Gem versus pemetrexed | ||||||||
Oettle H | 565 | palliative | Gem/Pem* | 283 | 60.4% | 63 (27-82) | 98.9% | 90.1% |
2005[30] | Â | Â | Gem | 282 | 53.5% | 63 (28-82) | 98.9% | 91.1% |
Gem versus Gem plus targeted therapy | ||||||||
Moore MJ | 569 | palliative | Gem/erlotinib | 285 | 47.7% | 64 (38-84) | 99.6% | 76.5% |
2007[31] | Â | Â | Gem | 284 | 57% | 64 (36-92) | 100% | 75% |
Van Cutsem E | 688 | first line | Gem/tipifarnib | 341 | 57% | 61 (29-89) | 100% | 76% |
2004[32] | Â | Â | Gem | 347 | 58% | 62 (30-88) | 100% | 77% |
Philip PA | 743 | palliative | Gem/Cetuximab | 372 | 51% | 63.7 | 100% | 79% |
2010[33] | Â | Â | Gem | 371 | 54% | 64.3 | 100% | 78% |
Saif MW | 135 | palliative | Gem/LY293111 | 67 | 60% | 62(33-82) | 99% | 87% |
2009[34] | Â | Â | Gem | 66 | 60% | 62(34-85) | 99% | 90% |
Spano JP | 103 | palliative | Gem/axitinib | 69 | 51% | 65(44-81) | 100% | 58% |
2008[35] | Â | Â | Gem | 34 | 47% | 61(36-78) | 100% | 56% |
Bramhall SR | 239 | first line | Gem/marimastat | 120 | 57.5% | 62 (32-83) | 100% | 59% |
2002[36] | Â | Â | Gem | 119 | 59.7% | 62 (37-85) | 100% | 62% |
Kindler HL | 602 | first line | Gem/Bev | 302 | 58% | 64 (26-88) | 100% | 84% |
2010[37] | Â | Â | Gem | 300 | 51% | 65 (35-86) | 100% | 85% |
Richards DA | 174 | first line | Gem/CI-994 | 86 | 59.3% | 62 (32-82) | 100% | 82.6% |
2006[38] | Â | Â | Gem | 88 | 60.2% | 65 (36-83) | 100% | 83% |
Friess H | 89 | first line | Gem/Cilengitide | 46 | 57% | 68 (40-80) | 100% | 93% |
2006[39] | Â | Â | Gem | 43 | 42% | 66 (56-80) | 100% | 90% |
the others | Â | Â | Â | Â | Â | Â | Â | Â |
Cascino S | 84 | first line | C-225/Gem/DDP | 42 | 69% | 61 (38-78) | 100% | 73.8% |
2008[40] | Â | Â | Gem/DDP | 42 | 52% | 64 (40-76) | 100% | 71.4% |
Vervenne W | 607 | first line | Gem/erlotinib/Bev | 306 | 57% | 62 | 100% | 100% |
2008[41] | Â | Â | Gem/erlotinib | 301 | 62% | 61 | 100% | 100% |
Boeck S | 190 | first line | Cap/Oxa | 61 | 65% | 62 (37-74) | 100% | 63% |
2007[42] | Â | Â | Gem/Cap | 64 | 57% | 63 (47-75) | 100% | 69% |
| Â | Â | Â | Gem/Oxa | 63 | 70% | 63 (45-75) | 100% | 71% |